J&J has been hunting for companies to buy. At the start of the year, the company’s new CEO Joaquin Duato said J&J would take a more “aggressive” approach to dealmaking, although he and other executives had indicated a preference toward small- and mid-sized acquisitions of medical technology and biotechnology companies.
Analysts had previously speculated that J&J could acquire a cardiology firm such as Boston Scientific.
In a statement, Duato said in the acquisition of Abiomed is “an important step in the execution of our strategic priorities” as the company focuses on its pharma and medtech businesses.
“We have committed to enhancing our position in medtech by entering high-growth segments,” he added. “The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.” READ MORE
by Elise Reuter
Source: biopharmadive.com
Samsung Biologics announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group, a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs).
Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems. The framework will enable pharmaceutical partners to access integrated data packages combining system-level testing and performance data for injectable therapies.
Brenntag has entered into a new strategic partnership with Evonik Rexim for the distribution of GMP-compliant amino acids in the European pharmaceutical and biopharmaceutical markets. The agreement covers most of Europe, including the DACH region, the United Kingdom, France, Benelux, Scandinavia, CEE, Israel, Turkey and more.
